ResMed Inc. (BVMF:R1MD34)

ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of BRL 194.45 billion. The enterprise value is 191.61 billion.

Market Cap	194.45B
Enterprise Value	191.61B

Important Dates

The next estimated earnings date is Thursday, January 22, 2026.

Earnings Date	Jan 22, 2026
Ex-Dividend Date	Nov 12, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.28%
Shares Change (QoQ)	-0.09%
Owned by Insiders (%)	0.53%
Owned by Institutions (%)	68.04%
Float	145.03M

Valuation Ratios

The trailing PE ratio is 25.37 and the forward PE ratio is 22.58.

PE Ratio	25.37
Forward PE	22.58
PS Ratio	6.94
PB Ratio	5.96
P/TBV Ratio	13.87
P/FCF Ratio	20.63
P/OCF Ratio	19.37
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.30, with an EV/FCF ratio of 20.33.

EV / Earnings	25.00
EV / Sales	6.90
EV / EBITDA	18.30
EV / EBIT	20.53
EV / FCF	20.33

Financial Position

The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.14.

Current Ratio	2.89
Quick Ratio	1.87
Debt / Equity	0.14
Debt / EBITDA	0.43
Debt / FCF	0.48
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.41% and return on invested capital (ROIC) is 16.93%.

Return on Equity (ROE)	25.41%
Return on Assets (ROA)	14.18%
Return on Invested Capital (ROIC)	16.93%
Return on Capital Employed (ROCE)	24.99%
Revenue Per Employee	2.64M
Profits Per Employee	722,940
Employee Count	10,600
Asset Turnover	0.68
Inventory Turnover	2.03

Taxes

In the past 12 months, ResMed has paid 1.61 billion in taxes.

Income Tax	1.61B
Effective Tax Rate	17.40%

Stock Price Statistics

The stock price has decreased by -8.56% in the last 52 weeks. The beta is 0.87, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.87
52-Week Price Change	-8.56%
50-Day Moving Average	348.90
200-Day Moving Average	311.55
Relative Strength Index (RSI)	36.09
Average Volume (20 Days)	53

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.23

Income Statement

In the last 12 months, ResMed had revenue of BRL 28.02 billion and earned 7.66 billion in profits. Earnings per share was 52.07.

Revenue	28.02B
Gross Profit	17.01B
Operating Income	9.39B
Pretax Income	9.28B
Net Income	7.66B
EBITDA	10.33B
EBIT	9.39B
Earnings Per Share (EPS)	52.07

Balance Sheet

The company has 7.38 billion in cash and 4.51 billion in debt, giving a net cash position of 2.86 billion.

Cash & Cash Equivalents	7.38B
Total Debt	4.51B
Net Cash	2.86B
Net Cash Per Share	n/a
Equity (Book Value)	32.62B
Book Value Per Share	223.53
Working Capital	12.63B

Cash Flow

In the last 12 months, operating cash flow was 10.04 billion and capital expenditures -612.83 million, giving a free cash flow of 9.42 billion.

Operating Cash Flow	10.04B
Capital Expenditures	-612.83M
Free Cash Flow	9.42B
FCF Per Share	n/a

Margins

Gross margin is 60.69%, with operating and profit margins of 33.52% and 27.35%.

Gross Margin	60.69%
Operating Margin	33.52%
Pretax Margin	33.11%
Profit Margin	27.35%
EBITDA Margin	36.87%
EBIT Margin	33.52%
FCF Margin	33.64%

Dividends & Yields

This stock pays an annual dividend of 2.10, which amounts to a dividend yield of 0.64%.

Dividend Per Share	2.10
Dividend Yield	0.64%
Dividend Growth (YoY)	12.06%
Years of Dividend Growth	5
Payout Ratio	22.31%
Buyback Yield	0.28%
Shareholder Yield	0.92%
Earnings Yield	3.94%
FCF Yield	4.85%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.67 and a Piotroski F-Score of 6.

Altman Z-Score	12.67
Piotroski F-Score	6